U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07211958) titled 'Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation' on Sept. 30.
Brief Summary: The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemias
Intervention:
DRUG: Revumenib
Participants will receive revumenib orally.
DRUG: Placebo
Participants will receive pl...